Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, parallel-group, single-dose, bioequivalence study of CHS-1420 compared with Humira in healthy subjects

Trial Profile

A double-blind, parallel-group, single-dose, bioequivalence study of CHS-1420 compared with Humira in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 15 Dec 2014 Status changed from recruiting to completed, according to Coherus BioSciences SEC filing report 10-Q 2014.
    • 19 Aug 2014 New trial record
    • 14 Aug 2014 Primary endpoint "area under the time-concentration curve: AUC0-t and AUC0-inf" has been met, according to a Coherus BioSciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top